Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) Capex-to-Operating-Income : 0.00 (As of Sep. 2023)

Hangzhou TianMuShan Pharmaceutical Enterprise Co Capex-to-Operating-Income Chart

Hangzhou TianMuShan Pharmaceutical Enterprise Co Annual Data
	Trend	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22
Capex-to-Operating-Income		Get a 7-Day Free Trial					4.05	-	-	-	-

Hangzhou TianMuShan Pharmaceutical Enterprise Co Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Capex-to-Operating-Income	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Hangzhou TianMuShan Pharmaceutical Enterprise Co's Capex-to-Operating-Income

For the Drug Manufacturers - General subindustry, Hangzhou TianMuShan Pharmaceutical Enterprise Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hangzhou TianMuShan Pharmaceutical Enterprise Co's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hangzhou TianMuShan Pharmaceutical Enterprise Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Hangzhou TianMuShan Pharmaceutical Enterprise Co's Capex-to-Operating-Income falls into.

Hangzhou TianMuShan Pharmaceutical Enterprise Co Capex-to-Operating-Income Calculation

Hangzhou TianMuShan Pharmaceutical Enterprise Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2022 is calculated as

Hangzhou TianMuShan Pharmaceutical Enterprise Co's Capex-to-Operating-Income for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hangzhou TianMuShan Pharmaceutical Enterprise Co  (SHSE:600671) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Hangzhou TianMuShan Pharmaceutical Enterprise Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Hangzhou TianMuShan Pharmaceutical Enterprise Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) Business Description